Skip to main content
. 2022 Mar 3;12:839915. doi: 10.3389/fonc.2022.839915

Table 2.

Reasons for dose reduction according to each TKI.

First-line(N=116) Second-line(N=63) Third-line or later(N=15) Overall(N=194)
Imatinib, n (AEs/MR) 47/32 3/0 0/1 50/33
Nilotinib, n (AEs/MR) 12/15 16/19 5/2 33/36
Dasatinib, n (AEs/MR) 6/4 12/10 4/0 22/14
Bosutinib, n (AEs/MR) 2/0 2/0
Ponatinib, n (AEs/MR) 1/2 1/0 2/2

AEs, adverse events; MR,molecular response.